Literature DB >> 19236625

Miglitol induces prolonged and enhanced glucagon-like peptide-1 and reduced gastric inhibitory polypeptide responses after ingestion of a mixed meal in Japanese Type 2 diabetic patients.

T Narita, Y Katsuura, T Sato, M Hosoba, H Fujita, T Morii, Y Yamada.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19236625     DOI： 10.1111/j.1464-5491.2008.02651.x

Source DB:  PubMed          Journal:  Diabet Med        ISSN： 0742-3071            Impact factor:   4.359


× No keyword cloud information.
  19 in total

Review 1.  Diabetes therapies in hemodialysis patients: Dipeptidase-4 inhibitors.

Authors:  Yuya Nakamura; Hitomi Hasegawa; Mayumi Tsuji; Yuko Udaka; Masatomo Mihara; Tatsuo Shimizu; Michiyasu Inoue; Yoshikazu Goto; Hiromichi Gotoh; Masahiro Inagaki; Katsuji Oguchi
Journal:  World J Diabetes       Date:  2015-06-25

Review 2.  Alogliptin: a review of its use in the management of type 2 diabetes mellitus.

Authors:  Lesley J Scott
Journal:  Drugs       Date:  2010-10-22       Impact factor: 9.546

3.  Effect of the addition of sitagliptin and miglitol on insulin-treated type 2 diabetes.

Authors:  Miyako Kishimoto; Mitsuhiko Noda
Journal:  Diabetes Ther       Date:  2012-09-28       Impact factor: 2.945

4.  A pilot study of the efficacy of miglitol and sitagliptin for type 2 diabetes with a continuous glucose monitoring system and incretin-related markers.

Authors:  Miyako Kishimoto; Mitsuhiko Noda
Journal:  Cardiovasc Diabetol       Date:  2011-12-22       Impact factor: 9.951

5.  Additive effects of miglitol and anagliptin on insulin-treated type 2 diabetes mellitus: a case study.

Authors:  Miyako Kishimoto; Mitsuhiko Noda
Journal:  Clin Drug Investig       Date:  2015-02       Impact factor: 2.859

6.  Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin compared with alpha-glucosidase inhibitor in Japanese patients with type 2 diabetes inadequately controlled on metformin or pioglitazone alone (Study for an Ultimate Combination Therapy to Control Diabetes with Sitagliptin-1): A multicenter, randomized, open-label, non-inferiority trial.

Authors:  Hidetaka Yokoh; Kazuki Kobayashi; Yasunori Sato; Minoru Takemoto; Daigaku Uchida; Azuma Kanatsuka; Nobuichi Kuribayashi; Takashi Terano; Naotake Hashimoto; Kenichi Sakurai; Hideki Hanaoka; Ko Ishikawa; Shunichiro Onishi; Koutaro Yokote
Journal:  J Diabetes Investig       Date:  2014-09-24       Impact factor: 4.232

7.  Effects of Miglitol, Acarbose, and Sitagliptin on Plasma Insulin and Gut Peptides in Type 2 Diabetes Mellitus: A Crossover Study.

Authors:  Hiroaki Ueno; Wakaba Tsuchimochi; Hong-Wei Wang; Eiichiro Yamashita; Chikako Tsubouchi; Kazuhiro Nagamine; Hideyuki Sakoda; Masamitsu Nakazato
Journal:  Diabetes Ther       Date:  2015-06-09       Impact factor: 2.945

Review 8.  A cardiologic approach to non-insulin antidiabetic pharmacotherapy in patients with heart disease.

Authors:  Enrique Z Fisman; Alexander Tenenbaum
Journal:  Cardiovasc Diabetol       Date:  2009-07-20       Impact factor: 9.951

9.  Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes.

Authors:  Miyako Kishimoto
Journal:  Diabetes Metab Syndr Obes       Date:  2013-05-06       Impact factor: 3.168

10.  Miglitol improves postprandial endothelial dysfunction in patients with acute coronary syndrome and new-onset postprandial hyperglycemia.

Authors:  Daisuke Kitano; Masaaki Chiku; Yuxin Li; Yasuo Okumura; Daisuke Fukamachi; Tadateru Takayama; Takafumi Hiro; Satoshi Saito; Atsushi Hirayama
Journal:  Cardiovasc Diabetol       Date:  2013-06-19       Impact factor: 9.951
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.